Cover Image
市場調查報告書

麴菌症:全球臨床實驗趨勢

Aspergillosis Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 229143
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
麴菌症:全球臨床實驗趨勢 Aspergillosis Global Clinical Trials Review, H1, 2017
出版日期: 2017年04月30日 內容資訊: 英文 115 Pages
簡介

本報告提供麴菌症相關臨床研究最新趨勢分析,彙整疾病·治療方法概要,及G7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:麴菌症臨床實驗數量佔感染疾病臨床實驗數量比率

各期臨床實驗數量:G7各國

G7各國的臨床實驗數量:各進展狀況

E7各國的臨床實驗數量:麴菌症臨床實驗數量佔感染疾病臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各進展狀況

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目臨別床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 麴菌症治療藥

有潛力的藥劑

最新臨床實驗新聞:麴菌症

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Aspergillosis Global Clinical Trials Review, H1, 2017" provides an overview of Aspergillosis clinical trials scenario. This report provides top line data relating to the clinical trials on Aspergillosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Five Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Aspergillosis to Infectious Disease Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Aspergillosis to Infectious Disease Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Aspergillosis Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on Aspergillosis 29
  • Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings 29
  • Clinical Trial Profile Snapshots 30

Appendix 113

  • Abbreviations 113
  • Definitions 113
  • Research Methodology 114
  • Secondary Research 114
  • About GlobalData 115
  • Contact Us 115
  • Source 115

List of Tables

List of Tables

  • Aspergillosis Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Aspergillosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Aspergillosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Aspergillosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Aspergillosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Aspergillosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Aspergillosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 13
  • Proportion of Aspergillosis to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 14
  • Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Aspergillosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Aspergillosis to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 17
  • Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Aspergillosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Aspergillosis Therapeutics, Global, Clinical Trials by Phase, 2017* 20
  • Aspergillosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
  • Aspergillosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Aspergillosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Aspergillosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Aspergillosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
  • Aspergillosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Aspergillosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Aspergillosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures

List of Figures

  • Aspergillosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Aspergillosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Aspergillosis Therapeutics, Global, Clinical Trials In Progress
Back to Top